These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 14750002)

  • 1. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis.
    Shaiova L; Lapin J; Manco LS; Shasha D; Hu K; Harrison L; Portenoy RK
    Support Care Cancer; 2004 Apr; 12(4):268-73. PubMed ID: 14750002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
    Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
    Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
    Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK
    Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series.
    Landy SH
    Headache; 2004 Sep; 44(8):762-6. PubMed ID: 15330821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral transmucosal fentanyl citrate versus placebo for painful dressing changes: a crossover trial.
    MacIntyre PA; Margetts L; Larsen D; Barker L
    J Wound Care; 2007 Mar; 16(3):118-21. PubMed ID: 17385588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain.
    Lichtor JL; Sevarino FB; Joshi GP; Busch MA; Nordbrock E; Ginsberg B
    Anesth Analg; 1999 Sep; 89(3):732-8. PubMed ID: 10475315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
    Mercadante S; Radbruch L; Davies A; Poulain P; Sitte T; Perkins P; Colberg T; Camba MA
    Curr Med Res Opin; 2009 Nov; 25(11):2805-15. PubMed ID: 19792837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients.
    Farrar JT; Cleary J; Rauck R; Busch M; Nordbrock E
    J Natl Cancer Inst; 1998 Apr; 90(8):611-6. PubMed ID: 9554444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.
    Christie JM; Simmonds M; Patt R; Coluzzi P; Busch MA; Nordbrock E; Portenoy RK
    J Clin Oncol; 1998 Oct; 16(10):3238-45. PubMed ID: 9779697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain.
    Payne R; Coluzzi P; Hart L; Simmonds M; Lyss A; Rauck R; Berris R; Busch MA; Nordbrook E; Loseth DB; Portenoy RK
    J Pain Symptom Manage; 2001 Jul; 22(1):575-83. PubMed ID: 11516599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fentanyl buccal tablet.
    Messina J; Darwish M; Fine PG
    Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study.
    Vasisht N; Gever LN; Tagarro I; Finn AL
    Clin Drug Investig; 2009; 29(10):647-54. PubMed ID: 19715381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis.
    Jandhyala R; Fullarton J
    BMJ Support Palliat Care; 2012 Jun; 2(2):156-62. PubMed ID: 24654058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
    Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
    Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study.
    Hanks GW; Nugent M; Higgs CM; Busch MA;
    Palliat Med; 2004 Dec; 18(8):698-704. PubMed ID: 15623166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
    Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of oral transmucosal fentanyl citrate for prehospital pain control on the battlefield.
    Wedmore IS; Kotwal RS; McManus JG; Pennardt A; Talbot TS; Fowler M; McGhee L
    J Trauma Acute Care Surg; 2012 Dec; 73(6 Suppl 5):S490-5. PubMed ID: 23192075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Vlahos L; Tsiatas ML
    Drug Deliv; 2006; 13(4):269-76. PubMed ID: 16766468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.